Programme

Assises Industrielles MAbImprove 2014 « MAbDosing »

Jeudi 3 juillet 2014, Hotel de l’Agglomération de Montpellier, France
(http://www.montpellier-agglo.com/equipement/hôtel-d-agglomération)

8h30-9h: Accueil

9h-9h30: Introduction

9h30-11h: Session 1

Therapeutic antibodies dosing: state-of-the-art in 2014
Gilles Paintaud, Université de Tours et CHRU, Tours, France

Dose selection for biologics in FIH trials
Antoine Deslandes, Sanofi R&D, Paris, France

PK/PD modeling and antibodies dosing
Candice Jamois, Roche, Basel, Switzerland

11h-11h30: Pause café

11h30-13h: Session 2

From body weight-based dosings to fixed dosings and from i.v. injection to s.c. administration: illustration with Trastuzumab
Dominique Breilh, CHRU, Bordeaux, France

Dose & administration scheme in antibodies combinations trials
Jérôme Tiollier, Innate Pharma, Marseille, France

Immuno-PET imaging to optimize disease targeting
Guus van Dongen, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands

13h-14h30: Déjeuner et discussion

14h30-16h30 : Session 3

Assessment of immunogenicity of biologics and its impact in preclinical and clinical studies
Pierre Cortez, Sanofi R&D, Montpellier, France

The regulatory perspective
Pierre Demolis, ANSM, Paris, France

Criteria influencing dose selection of biologic therapies from drug development to market
Eric Didier, Pierre Fabre, Saint Julien en Genevois, France

Preclinical pharmacokinetic studies as a mechanistic support for therapeutic antibodies development
Pascal Delrat, Servier, Orléans, France